{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T11:51:15Z","timestamp":1770983475663,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","award":["N01MH90001"],"award-info":[{"award-number":["N01MH90001"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ClinicalTrials.gov identifier","award":["NCT00014001"],"award-info":[{"award-number":["NCT00014001"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.euroneuro.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T22:15:33Z","timestamp":1395180933000},"page":"1078-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study"],"prefix":"10.1016","volume":"24","author":[{"given":"Gagan","family":"Fervaha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Agid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyoshi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Foussias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.03.001_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1524-4733.2008.00495.x","article-title":"Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study","volume":"12","author":"Alonso","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib3","series-title":"MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR)","author":"Appelbaum","year":"2001"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib6","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.schbul.a033484","article-title":"Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia","volume":"26","author":"Cramer","year":"2000","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1037\/0033-2909.95.3.542","article-title":"Subjective well-being","volume":"95","author":"Diener","year":"1984","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1207\/s15327752jpa4901_13","article-title":"The Satisfaction With Life Scale","volume":"49","author":"Diener","year":"1985","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/schbul\/sbl071","article-title":"Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis","volume":"33","author":"Eack","year":"2007","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.schres.2013.10.021","article-title":"Clinical determinants of life satisfaction in chronic schizophrenia: data from the CATIE study","volume":"151","author":"Fervaha","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib12","series-title":"User\u05f3s Guide for the Structured Clinical Interview for DSM-IV axis I Disorders SCID-I: Clinician Version","author":"First","year":"1997"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jama.1994.03520080061045","article-title":"A critical appraisal of the quality of quality-of-life measurements","volume":"272","author":"Gill","year":"1994","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib14","series-title":"ECDEU Assessment Manual for Psychopharmacology\u2014Revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib21","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.npp.1301072","article-title":"Baseline neurocognitive deficits in the CATIE schizophrenia trial","volume":"31","author":"Keefe","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.schbul.a006990","article-title":"Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale","volume":"29","author":"Keefe","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1983.01790040023003","article-title":"The well-being of chronic mental patients","volume":"40","author":"Lehman","year":"1983","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0149-7189(88)90033-X","article-title":"A quality of life interview for the chronically mentally ill","volume":"11","author":"Lehman","year":"1988","journal-title":"Eval. Program Plan."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib25","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF00449427","article-title":"Convergent validation of quality of life assessments for persons with severe mental illnesses","volume":"2","author":"Lehman","year":"1993","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/schbul\/sbp044","article-title":"Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel","volume":"37","author":"Leifker","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1300873","article-title":"The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00005053-198901000-00007","article-title":"Insight in schizophrenia. Its relationship to acute psychopathology","volume":"177","author":"McEvoy","year":"1989","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib32","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/NMD.0b013e3181fe7258","article-title":"The development of subjective quality of life over the first 2 years in first-episode psychosis","volume":"198","author":"Melle","year":"2010","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/scientificamerican0596-70","article-title":"The pursuit of happiness","volume":"274","author":"Myers","year":"1996","journal-title":"Sci. Am."},{"issue":"Suppl. 3","key":"10.1016\/j.euroneuro.2014.03.001_bib36","first-page":"S133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10","author":"Naber","year":"1995","journal-title":"Int. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2007.09.001","article-title":"Subjective and objective quality of life in schizophrenia","volume":"98","author":"Narvaez","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib38","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders","volume":"162","author":"Rapaport","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1034\/j.1600-0447.2003.00132.x","article-title":"Depression and subjective quality of life in chronic phase schizophrenic patients","volume":"108","author":"Reine","year":"2003","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11530250-000000000-00000","article-title":"Progress in defining optimal treatment outcome in schizophrenia","volume":"24","author":"Remington","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11136-005-2808-9","article-title":"Determinants of changes in perceived quality of life in the course of schizophrenia","volume":"15","author":"Ritsner","year":"2006","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2008.09.031","article-title":"Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial","volume":"107","author":"Rosenheck","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib44","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/S0277-9536(99)00045-3","article-title":"Integrating response shift into health-related quality of life research: a theoretical model","volume":"48","author":"Sprangers","year":"1999","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.10.011","article-title":"Results of phase 3 of the CATIE schizophrenia trial","volume":"107","author":"Stroup","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1176\/ajp.2007.164.3.415","article-title":"Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study","volume":"164","author":"Stroup","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","article-title":"The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development","volume":"29","author":"Stroup","year":"2003","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2014.03.001_bib49","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/ajp.2007.164.3.428","article-title":"Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study","volume":"164","author":"Swartz","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.03.001_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0033291797005874","article-title":"Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability","volume":"28","author":"Voruganti","year":"1998","journal-title":"Psychol. Med."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14000868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14000868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:32Z","timestamp":1760377832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14000868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0924977X14000868"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of antipsychotic medication on overall life satisfaction among individuals with chronic schizophrenia: Findings from the NIMH CATIE study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}